Generic semaglutide is coming to Canada
Health Canada is reviewing nine generic semaglutide submissions from manufacturers including Sandoz, Apotex, and Teva. Here's where the approval process stands today.
Approval timeline
Based on publicly available Health Canada filings and regulatory timelines.
October 30, 2025
Dr. Reddy’s Laboratories received a Notice of Non-Compliance from Health Canada on its generic semaglutide submission, delaying its timeline by 8–12 months
December 22, 2025
Health Canada approved Plosbrio and Poviztra — Novo Nordisk’s lower-cost rebrands of Ozempic and Wegovy, respectively — as a strategy to compete with upcoming generics
January 4, 2026
Novo Nordisk’s data exclusivity for semaglutide expired in Canada, opening the door for generic manufacturers
January 2026
Seven generic semaglutide submissions under Health Canada review from five companies: Sandoz Canada, Apotex (three separate submissions), Taro Pharmaceuticals, Aspen Pharmacare, and Teva Canada
February 2, 2026
PharmaTher announced a strategic initiative to pursue Health Canada approval for generic semaglutide, targeting broad dose coverage (0.25 mg to 2.4 mg)
Expected Q3 2026
Earliest Health Canada decisions on generic semaglutide approvals, per Sandoz and industry estimates (Health Canada’s review backlog may extend timelines)
After approval
Generic semaglutide available at Canadian pharmacies at significantly lower prices
Timeline is based on public information only. GLP1Prices does not have advance knowledge of Health Canada decisions.
The next milestone could happen any day. Don't miss it.
Get notified when generic semaglutide is approved and prices are listed in Canada.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
What you'll receive
- Email notification when generic semaglutide prices are first listed
- Price comparison across Canadian pharmacies — in your province
- No spam — one email when prices are live, unsubscribe any time